Alchemab Therapeutics unveils Alzheimer’s candidate ATLX-1088 targeting CD33 at the Antibody Industrial Symposium
CAMBRIDGE, England, June 22, 2023 /PRNewswire/ — Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announced that it unveiled data on ATLX-1088, its newly-discovered preclinical Alzheimer’s candidate, at the Antibody Industrial Symposium in Tours, France, 22-23 June 2023. ATLX-1088 is a potential first-in-class human antibody targeting CD33, … Read more